277 related articles for article (PubMed ID: 29523966)
1. Soluble CD163 and soluble CD14 plasma levels but not cellular HIV-DNA decrease during successful interferon-free anti-HCV therapy in HIV-1-HCV co-infected patients on effective combined anti-HIV treatment.
Parisi SG; Andreis S; Mengoli C; Menegotto N; Cavinato S; Scaggiante R; Andreoni M; Palù G; Basso M; Cattelan AM
Med Microbiol Immunol; 2018 Aug; 207(3-4):183-194. PubMed ID: 29523966
[TBL] [Abstract][Full Text] [Related]
2. Time course of cellular HIV-DNA and low-level HIV viremia in HIV-HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals.
Parisi SG; Andreis S; Basso M; Cavinato S; Scaggiante R; Franzetti M; Andreoni M; Palù G; Cattelan AM
Med Microbiol Immunol; 2017 Dec; 206(6):419-428. PubMed ID: 28864951
[TBL] [Abstract][Full Text] [Related]
3. Higher CD163 levels are associated with insulin resistance in hepatitis C virus-infected and HIV-infected adults.
Reid M; Ma Y; Scherzer R; Price JC; French AL; Plankey MW; Grunfeld C; Tien PC
AIDS; 2017 Jan; 31(3):385-393. PubMed ID: 28081037
[TBL] [Abstract][Full Text] [Related]
4. During Hepatitis C Virus (HCV) Infection and HCV-HIV Coinfection, an Elevated Plasma Level of Autotaxin Is Associated With Lysophosphatidic Acid and Markers of Immune Activation That Normalize During Interferon-Free HCV Therapy.
Kostadinova L; Shive CL; Judge C; Zebrowski E; Compan A; Rife K; Hirsch A; Falck-Ytter Y; Schlatzer DM; Li X; Chance MR; Rodriguez B; Popkin DL; Anthony DD
J Infect Dis; 2016 Nov; 214(9):1438-1448. PubMed ID: 27540113
[TBL] [Abstract][Full Text] [Related]
5. Active HCV infection is associated with increased circulating levels of interferon-gamma (IFN-γ)-inducible protein-10 (IP-10), soluble CD163 and inflammatory monocytes regardless of liver fibrosis and HIV coinfection.
Mascia C; Lichtner M; Zuccalà P; Vita S; Tieghi T; Marocco R; Savinelli S; Rossi R; Iannetta M; Campagna M; Schiavone F; Mengoni F; Russo G; Mastroianni CM; Vullo V
Clin Res Hepatol Gastroenterol; 2017 Dec; 41(6):644-655. PubMed ID: 28578937
[TBL] [Abstract][Full Text] [Related]
6. Unchanged Levels of Soluble CD14 and IL-6 Over Time Predict Serious Non-AIDS Events in HIV-1-Infected People.
Sunil M; Nigalye M; Somasunderam A; Martinez ML; Yu X; Arduino RC; Utay NS; Bell TK
AIDS Res Hum Retroviruses; 2016 Dec; 32(12):1205-1209. PubMed ID: 27344921
[TBL] [Abstract][Full Text] [Related]
7. Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology.
Lund Laursen T; Brøckner Siggard C; Kazankov K; Damgaard Sandahl T; Møller HJ; Ong A; Douglas MW; George J; Tarp B; Hagelskjaer Kristensen L; Lund Laursen A; Hiramatsu A; Nakahara T; Chayama K; Grønbaek H
Scand J Gastroenterol; 2018 Aug; 53(8):986-993. PubMed ID: 29987961
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C Virus Cure in Human Immunodeficiency Virus Coinfection Dampens Inflammation and Improves Cognition Through Multiple Mechanisms.
Sun B; Abadjian L; Monto A; Freasier H; Pulliam L
J Infect Dis; 2020 Jul; 222(3):396-406. PubMed ID: 32157304
[TBL] [Abstract][Full Text] [Related]
9. The macrophage activation marker CD163 is associated with IL28B genotype and hepatic inflammation in chronic hepatitis C virus infected patients.
Dultz G; Gerber L; Zeuzem S; Sarrazin C; Waidmann O
J Viral Hepat; 2016 Apr; 23(4):267-73. PubMed ID: 26554542
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of soluble CD163 and soluble CD14 following antibiotic therapy of patients with acute brucellosis.
Sun H; Jiang R; Han B; Du X; Ma C; Xu Y; Chen Z; Wang L; Yang S; Lv X; Zhao H; Li X
J Infect Dev Ctries; 2019 Aug; 13(8):714-719. PubMed ID: 32069255
[TBL] [Abstract][Full Text] [Related]
11. Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection.
Beltrán LM; Muñoz Hernández R; de Pablo Bernal RS; García Morillo JS; Egido J; Noval ML; Ferrando-Martinez S; Blanco-Colio LM; Genebat M; Villar JR; Moreno-Luna R; Moreno JA
PLoS One; 2014; 9(3):e90541. PubMed ID: 24594990
[TBL] [Abstract][Full Text] [Related]
12. Plasma CXCL10, sCD163 and sCD14 Levels Have Distinct Associations with Antiretroviral Treatment and Cardiovascular Disease Risk Factors.
Castley A; Williams L; James I; Guelfi G; Berry C; Nolan D
PLoS One; 2016; 11(6):e0158169. PubMed ID: 27355513
[TBL] [Abstract][Full Text] [Related]
13. Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection.
Lidofsky A; Holmes JA; Feeney ER; Kruger AJ; Salloum S; Zheng H; Seguin IS; Altinbas A; Masia R; Corey KE; Gustafson JL; Schaefer EA; Hunt PW; Deeks S; Somsouk M; Chew KW; Chung RT; Alatrakchi N
J Infect Dis; 2018 Sep; 218(9):1394-1403. PubMed ID: 29868909
[TBL] [Abstract][Full Text] [Related]
14. Low levels of microbial translocation marker LBP are associated with sustained viral response after anti-HCV treatment in HIV-1/HCV co-infected patients.
Nyström J; Stenkvist J; Häggblom A; Weiland O; Nowak P
PLoS One; 2015; 10(3):e0118643. PubMed ID: 25785448
[TBL] [Abstract][Full Text] [Related]
15. Short Communication: SCD14 and SCD163 Levels Are Correlated with VACS Index Scores: Initial Data from the Blunted Immune Recovery in CORE Patients with HIV (BIRCH) Cohort.
Williams B; Livak B; Bahk M; Keating SM; Adeyemi OM
AIDS Res Hum Retroviruses; 2016 Feb; 32(2):144-7. PubMed ID: 26366931
[TBL] [Abstract][Full Text] [Related]
16. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients.
Burdo TH; Lo J; Abbara S; Wei J; DeLelys ME; Preffer F; Rosenberg ES; Williams KC; Grinspoon S
J Infect Dis; 2011 Oct; 204(8):1227-36. PubMed ID: 21917896
[TBL] [Abstract][Full Text] [Related]
17. Persistent high plasma levels of sCD163 and sCD14 in adult patients with measles virus infection.
Mascia C; Pozzetto I; Kertusha B; Marocco R; Del Borgo C; Tieghi T; Vita S; Savinelli S; Iannetta M; Vullo V; Lichtner M; Mastroianni CM
PLoS One; 2018; 13(5):e0198174. PubMed ID: 29795672
[TBL] [Abstract][Full Text] [Related]
18. Brief Report: Soluble CD163 in CMV-Infected and CMV-Uninfected Subjects on Virologically Suppressive Antiretroviral Therapy in the ICONA Cohort.
Vita S; Lichtner M; Marchetti G; Mascia C; Merlini E; Cicconi P; Vullo V; Viale P; Costantini A; DʼArminio Monforte A;
J Acquir Immune Defic Syndr; 2017 Mar; 74(3):347-352. PubMed ID: 27828874
[TBL] [Abstract][Full Text] [Related]
19. Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon.
Mascia C; Vita S; Zuccalà P; Marocco R; Tieghi T; Savinelli S; Rossi R; Iannetta M; Pozzetto I; Furlan C; Mengoni F; Mastroianni CM; Vullo V; Lichtner M
PLoS One; 2017; 12(6):e0179400. PubMed ID: 28636655
[TBL] [Abstract][Full Text] [Related]
20. Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy.
Burdo TH; Lentz MR; Autissier P; Krishnan A; Halpern E; Letendre S; Rosenberg ES; Ellis RJ; Williams KC
J Infect Dis; 2011 Jul; 204(1):154-63. PubMed ID: 21628670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
